RAPP
Rapport Therapeutics, Inc.Company with tickers: RAPP
CIK
2012593
CUSIP
75383L102
Shares Outstanding
47,826,929
Website
https://www.rapportrx.com
13F Activity (30d)
3 filings
2 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $20,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $44,215,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $32,716,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-24,215,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-19,857,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.42 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.42 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |